[Chinese expert consensus on the ethical review of clinical research of ophthalmic gene therapy (2022)].

The eye is considered as the best targeted organ for gene therapy, which has become a hot field of ophthalmic clinical trials in recent years. Since the risk of gene therapy is usually high, it is important to standardize the ethical review of related clinical research, so as to better protect the rights of patients and promote the innovative research. Thus, after several rounds of discussion, the experts from Chinese Vitreo-Retina Society of Chinese Medical Association and Fundus Disease Committee of Chinese Ophthalmologist Association have proposed the formal ethical review guidelines (International Practice Guideline Registration Number: IPGRP-2022CN347), which would play a role in standardizing clinical practice with gene therapy.